Anplag Tab. 100mg bid + Anplag Tab. 100mg tid
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Peripheral Artery Disease, PAD
Conditions
Peripheral Artery Disease, PAD
Trial Timeline
Oct 11, 2018 → Mar 5, 2020
NCT ID
NCT03509922About Anplag Tab. 100mg bid + Anplag Tab. 100mg tid
Anplag Tab. 100mg bid + Anplag Tab. 100mg tid is a approved stage product being developed by Yuhan for Peripheral Artery Disease, PAD. The current trial status is completed. This product is registered under clinical trial identifier NCT03509922. Target conditions include Peripheral Artery Disease, PAD.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03509922 | Approved | Completed |
Competing Products
20 competing products in Peripheral Artery Disease, PAD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SON-080 | Sonnet BioTherapeutics | Phase 1/2 | 36 |
| LY3857210 + Placebo | Eli Lilly | Phase 2 | 52 |
| Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg | Yuhan | Approved | 85 |
| YHD1119 + Lyrica | Yuhan | Phase 1 | 33 |
| YHD1119 + Lyrica | Yuhan | Phase 1 | 33 |
| YHD1119 + Lyrica | Yuhan | Phase 3 | 77 |
| YHD1119 300mg + YHD1119 300mg | Yuhan | Phase 1 | 33 |
| DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsule | Daiichi Sankyo | Phase 2 | 52 |
| edoxaban + Clopidogrel + Aspirin | Daiichi Sankyo | Phase 2 | 52 |
| DS-5565 + placebo | Daiichi Sankyo | Phase 3 | 77 |
| Mirogabalin + Placebo | Daiichi Sankyo | Phase 3 | 77 |
| DS-5565 | Daiichi Sankyo | Phase 3 | 77 |
| Valemetostat Tosylate | Daiichi Sankyo | Phase 2 | 52 |
| ASP3662 + pregabalin + ASP3662 placebo + pregabalin placebo | Astellas Pharma | Phase 2 | 52 |
| Qutenza | Astellas Pharma | Pre-clinical | 23 |
| QUTENZA + Lidocaine + Tramadol | Astellas Pharma | Approved | 85 |
| Qutenza exposure | Astellas Pharma | Pre-clinical | 23 |
| QUTENZA | Astellas Pharma | Phase 3 | 77 |
| Qutenza + Pregabalin | Astellas Pharma | Approved | 85 |
| Capsaicin 8% + Placebo | Astellas Pharma | Phase 3 | 77 |
Other Products from Yuhan
generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85
Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mgApproved
85